Back

The SGLT2 inhibitor empagliflozin reduces mortality in experimental pulmonary hypertension

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Novel pharmacological targets in vascular disease Hypertension, Pulmonary Hypertension ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Subodh Verma

St. Michael's Hospital, Toronto (Canada)

4 More presentations in this session

Presentation thumbnail
State of the Art - Metabolic aspects of vascular disease
Professor M. Federici (Rome, IT)
Slides Video
Presentation thumbnail
Role of the gut microbiome for the cholesterol lowering effect of atorvastatin
Miss F. Zimmermann (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
Identification of celastramycin as a novel therapeutic agent for pulmonary arterial hypertension -high-throughput screening of 5,562 compounds-
Doctor R. Kurosawa (Yokohama, JP)
Abstract Slides Video
Presentation thumbnail
Microparticles from vascular endothelial growth factor pathway inhibitor-treated cancer patients mediate endothelial cell injury
Professor R. Touyz (Montreal, CA)
Slides Video

Access the full session

Session thumbnail
Novel pharmacological targets in vascular disease

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources